Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label randomized 96-week first-line HIV-1 trial comparing darunavir/ritonavir + raltegravir versus darunavir/ritonavir + tenofovir/emtricitabine
2009-015113-44Phase 3Completed
- Sponsor
- ANSR
- Start
- Feb 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in Human immunodeficiency virus infection type 1 comparing Darunavir/ritonavir + raltegravir with Darunavir/ritonavir + tenofovir/emtricitabine (2 arms). Primary endpoints: Time to virologic or clinical failure and Non-inferiority of darunavir/ritonavir + raltegravir. Started Feb 2010; status: completed.
02
Drugs
darunavirritonavirraltegravirtenofoviremtricitabine
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2009-015113-44.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-015113-44.